Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment of Vitamin D Deficiency in Decompensated Patients with Cirrhosis Is Associated with Improvement in Frailty

  • Díaz Ruíz, Raquel|||0000-0002-2259-0289
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Roman, Eva|||0000-0001-9084-8555
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Bañares, Irene
  • Morales, Ángela
  • Hernández Martínez-Esparza, Elvira|||0000-0002-9736-9052
  • Panadero, Rocío
  • Velasco, Cristina
  • Rapado-Castro, Marta|||0000-0001-8484-6051
  • Breton, Irene|||0000-0003-0263-3728
  • Bañares, Rafael|||0000-0002-0412-8437
  • Soriano, German|||0000-0002-9267-6811
  • García Martínez, Rita|||0000-0003-2159-2757
Background/aim : Frailty is increasingly recognized as a relevant prognostic factor in patients with cirrhosis, regardless of liver failure. Vitamin D deficiency is frequent in these patients and has been related to frailty and sarcopenia, but the impact of its supplementation on frailty in cirrhosis is unknown. The aim was to evaluate the effect of vitamin D supplementation on frailty in patients with decompensated cirrhosis and vitamin D deficiency or insufficiency. Methods : We included patients with cirrhosis who had vitamin D deficiency or insufficiency following their hospitalization for acute decompensation. Vitamin D was supplemented according to current recommendations, as were other micronutrients if necessary. Patients were followed for one year to evaluate changes at 6 and 12 months in frailty (Fried frailty index), health-related quality of life (SF-36, CLDQ) and mood (HADS). Body composition was assessed by DXA at baseline and at 12 months. Results : We included 39 patients, 27 of whom reached the 6-month follow-up. Serum vitamin D increased at 6 and 12 months (p < 0.001 compared to baseline). Fried frailty index improved at the 6-month visit (p = 0.004), and handgrip strength improved at 6 (p = 0.001) and 12 (p = 0.002) months, similarly in women and men. At 12 months, we observed an increase in body mass index, right arm lean mass and total fat mass. Conclusions : A multifactorial nutritional intervention, especially vitamin D supplementation after discharge in decompensated, vitamin D-deficient patients with cirrhosis, was associated with an improvement in frailty, muscular strength and lean muscle mass. However, the increase in fat mass strengthens the recommendation for diet, exercise and weight supervision.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis

  • Díaz Ruíz, Raquel|||0000-0002-2259-0289
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Roman, Eva|||0000-0001-9084-8555
  • Panadero, Rocío
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Bañares, Irene
  • Morales, Ángela
  • Puerto, Marta|||0000-0002-1263-9296
  • Lopez-Esteban, Rocio
  • Blazquez, Elena
  • Fernández-Castillo, Marta
  • Correa-Rocha, Rafael|||0000-0003-3456-9986
  • Rapado-Castro, Marta|||0000-0001-8484-6051
  • Breton, Irene|||0000-0003-0263-3728
  • Bañares, Rafael|||0000-0002-0412-8437
  • Soriano, German|||0000-0002-9267-6811
  • García Martínez, Rita|||0000-0003-2159-2757
Background/Objectives: Decompensated cirrhosis is characterized by systemic inflammation and innate and adaptive immune dysfunction. Hepatic encephalopathy (HE) is a prevalent and debilitating condition characterized by cognitive disturbances in which ammonia and inflammation play a synergistic pathogenic role. Extraskeletal functions of vitamin D include immunomodulation, and its deficiency has been implicated in immune dysfunction and different forms of cognitive impairment. The aim was to assess changes in cognitive function and inflammation in decompensated patients with cirrhosis receiving vitamin D supplementation. Methods : Patients with cirrhosis discharged from decompensation in two tertiary hospitals in Spain (from September 2017 to January 2020) were assessed before, at 6 and 12 months after vitamin D supplementation. A comprehensive neuropsychological battery and neuroinflammatory markers were examined. In a subgroup of patients, peripheral immune blood cells were analyzed. Results : Thirty-nine patients were recruited. Of those, 27 completed the 6 months evaluation and were analyzed [age 62.4 ± 11.3 years; 22 men; Model for End-Stage Liver Disease (MELD) 11.7 ± 4.0; prior overt HE 33%; median 25-hydroxyvitamin D (25OHD) plasma level 12.7 µgr/L] and 22 achieved 12 months assessment. At baseline, learning and memory (R = 0.382; p = 0.049) and working memory (R = 0.503; p = 0.047) subtests correlated with plasma 25OHD levels. In addition, processing speed (R = -0.42; p = 0.04), attention (R = -0.48; p = 0.04), Tinnetti balance (R = -0.656; p < 0.001) and Tinnetti score (R = -0.659; p < 0.001) were linked to neuroinflammation marker IL-1β. Patients with lower 25OHD had a greater proportion of TH1cells at baseline and a larger amelioration of IL-1β and IL-6 following supplementation. An improvement in working memory was found after 25OHD replacement (46.7 ± 13 to 50 ± 11; p = 0.047). Conclusions : This study supports that vitamin D supplementation modulates low-grade inflammation in decompensated cirrhosis providing cognitive benefits, particularly in working memory.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Increased consumption of virgin olive oil, nuts, legumes, whole grains, and fish promotes HDL functions in humans

  • Hernáez, Álvaro
  • Sanllorente Melenchon, Albert
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • de la Torre, Rafael
  • Lamuela Raventós, Rosa Ma.
  • Fitó Colomer, Montserrat
Scope To evaluate whether increases in the consumption of cardioprotective food groups (virgin olive oil, nuts, fruits/vegetables, legumes, whole grains, fish, and wine) are associated with improvements in high-density lipoprotein (HDL) functions in high cardiovascular risk subjects. Methods and Results The association between 1-year changes in food group consumption and HDL functionality traits in 296 high cardiovascular risk subjects is assessed. Increases in virgin olive oil (10 g d–1) and whole grain consumption (25 g d–1) are associated with increments in cholesterol efflux capacity (+0.7%, P = 0.026, and +0.6%, P = 0.017, respectively). Increases in nut (30 g d–1) and legume intake (25 g d–1) are linked to increments in paraoxonase-1 activity (+12.2%, P = 0.049, and +11.7%, P = 0.043, respectively). Legume intake increases are also related to decreases in cholesteryl ester transfer protein activity (–4.8%, P = 0.028). Fish consumption increments (25 g d–1) are associated with increases in paraoxonase-1 activity (+3.9%, P = 0.030) and declines in cholesteryl ester transfer protein activity (–1.6%, P = 0.021), HDL cholesterol concentrations (–1.1%, P = 0.039), and functions related to HDL levels (cholesterol efflux capacity, –1.1%, P = 0.010). Conclusion Increases in the consumption of virgin olive oil, nuts, legumes, whole grains, and fish (achievable through a regular diet) were associated with improvements in HDL functions in high cardiovascular risk subjects., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Increased consumption of virgin olive oil, nuts, legumes, whole grains, and fish promotes HDL functions in humans

  • Hernáez, Álvaro
  • Sanllorente Melenchon, Albert
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • de la Torre, Rafael
  • Lamuela Raventós, Rosa Ma.
  • Fitó Colomer, Montserrat
Scope To evaluate whether increases in the consumption of cardioprotective food groups (virgin olive oil, nuts, fruits/vegetables, legumes, whole grains, fish, and wine) are associated with improvements in high-density lipoprotein (HDL) functions in high cardiovascular risk subjects. Methods and Results The association between 1-year changes in food group consumption and HDL functionality traits in 296 high cardiovascular risk subjects is assessed. Increases in virgin olive oil (10 g d–1) and whole grain consumption (25 g d–1) are associated with increments in cholesterol efflux capacity (+0.7%, P = 0.026, and +0.6%, P = 0.017, respectively). Increases in nut (30 g d–1) and legume intake (25 g d–1) are linked to increments in paraoxonase-1 activity (+12.2%, P = 0.049, and +11.7%, P = 0.043, respectively). Legume intake increases are also related to decreases in cholesteryl ester transfer protein activity (–4.8%, P = 0.028). Fish consumption increments (25 g d–1) are associated with increases in paraoxonase-1 activity (+3.9%, P = 0.030) and declines in cholesteryl ester transfer protein activity (–1.6%, P = 0.021), HDL cholesterol concentrations (–1.1%, P = 0.039), and functions related to HDL levels (cholesterol efflux capacity, –1.1%, P = 0.010). Conclusion Increases in the consumption of virgin olive oil, nuts, legumes, whole grains, and fish (achievable through a regular diet) were associated with improvements in HDL functions in high cardiovascular risk subjects., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer

  • Sebio, Ana|||0000-0003-3333-2370
  • Matsusaka, Satoshi
  • Zhang, Wu
  • Yang, Dongyun
  • Ning, Yan
  • Stremitzer, Stefan
  • Stintzing, Sebastian
  • Sunakawa, Yu
  • Yamauchi, Shinichi
  • Fujimoto, Yoshiya
  • Ueno, Masaki
  • Lenz, Heinz-Josef
The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil. In this study 14 polymorphisms in 8 genes involved in the Hippo pathway (MST1, MST2, LATS1, LATS2, YAP, TAZ, FAT4 and RASSF1A) were evaluated as recurrence predictors in 194 patients with stages II/III colon cancer treated with 5-Fu-based adjuvant chemotherapy. Patients with a RASSF1A rs2236947 AA genotype had higher 3-year recurrence rate than patients with CA/CC genotypes (56% vs 33%, HR: 1.87; p =0.017). Patients with TAZ rs3811715 CT or TT genotypes had lower 3-year recurrence rate than patients with a CC genotype (28% vs 40%; HR: 0.66; p =0.07). In left-sided tumors, this association was stronger (HR: 0.29; p =0.011) and a similar trend was found in an independent Japanese cohort. These promising results reveal polymorphisms in the Hippo pathway as biomarkers for stage II and III colon cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy, results from FIRE-3 and JACCRO 05 and 06 trials

  • Sebio, A.
  • Stintzing, Sebastian
  • Heinemann, V.
  • Sunakawa, Yu
  • Zhang, W.
  • Ichikawa, W.
  • Tsuji, A.
  • Takahashi, T.
  • Parek, A.
  • Yang, Dawei
  • Cao, S.
  • Ning, Y.
  • Stremitzer, Stefan
  • Matsusaka, Satoshi
  • Okazaki, S.
  • Barzi, A.
  • Berger, M.
  • Lenz, H-J
The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated with cetuximab. Two cohorts treated with cetuximab plus chemotherapy were evaluated (198 RAS wild-type (wt) patients treated with first-line FOLFIRI plus Cetuximab within the FIRE-3 trial and 67 Ras wt patients treated either with first-line mFOLFOX6 or SOX plus Cetuximab). In these two populations, Rassf1a rs2236947 was associated with overall survival, as patients with a CC genotype had significantly longer OS compared to those with CA or AA genotypes. This association was stronger in patients with left-side CRC [HR: 1.79 (1.01-3.14); P =0.044 and HR: 2.83 (1.14-7.03); P =0.025, for Fire 3 and JACCRO cohorts, respectively]. Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Gut Microbiome Profile in Obesity, A Systematic Review

  • Castañer, Olga|||0000-0003-3169-997X
  • Goday Arnó, Albert|||0000-0001-7356-1595
  • Park, Yong-Moon
  • Lee, Seung-Hwan|||0000-0002-3964-3877
  • Magkos, Faidon
  • Shiow, Sue-Anne Toh Ee
  • Schröder, Helmut|||0000-0003-2231-5081
Gut microbiome has been identified in the past decade as an important factor involved in obesity, but the magnitude of its contribution to obesity and its related comorbidities is still uncertain. Among the vast quantity of factors attributed to obesity, environmental, dietary, lifestyle, genetic, and others, the microbiome has aroused curiosity, and the scientific community has published many original articles. Most of the studies related to microbiome and obesity have been reported based on the associations between microbiota and obesity, and the in-depth study of the mechanisms related has been studied mainly in rodents and exceptionally in humans. Due to the quantity and diverse information published, the need of reviews is mandatory to recapitulate the relevant achievements. In this systematic review, we provide an overview of the current evidence on the association between intestinal microbiota and obesity. Additionally, we analyze the effects of an extreme weight loss intervention such as bariatric surgery on gut microbiota. The review is divided into 2 sections: first, the association of obesity and related metabolic disorders with different gut microbiome profiles, including metagenomics studies, and second, changes on gut microbiome after an extreme weight loss intervention such as bariatric surgery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

  • López-Anglada, Lucía|||0000-0003-1727-8546
  • Cueto-Felgueroso, Cecilia|||0000-0002-4329-9634
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Oriol, Albert|||0000-0001-6804-2221
  • Teruel, Ana Isabel|||0000-0003-1559-7607
  • López de la Guía, Ana|||0000-0002-7705-7844
  • Bengoechea, Enrique
  • Palomera, Luis|||0000-0003-0359-7191
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Hernandez, Jose Mariano
  • Granell, Miquel|||0000-0002-0366-3673
  • Peñalver, Francisco Javier
  • García-Sanz, Ramón|||0000-0003-4120-2787
  • Besalduch, Joan
  • Gonzalez Montes, Yolanda|||0000-0002-4471-5142
  • Martinez, Rafael Benigno
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Gutierrez, Norma C.
  • Puerta, Paloma
  • Valeri, Antonio
  • Paiva, Bruno|||0000-0003-1977-3815
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Mateos, M. V.|||0000-0003-2390-1218
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Martínez-López, Joaquín|||0000-0001-7908-0063
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. Serum samples collected at diagnosis were retrospectively analyzed for sFLC (n = 623) and sHLC (n = 183). After induction or autologous transplantation, 309 and 89 samples respectively were available for sFLC and sHLC assays. At diagnosis, a highly abnormal (HA) sFLC ratio (sFLCr) (<0.03 or.